The choice of vascular access for kidney dialysis patients represents a critical decision point that could extend survival by over two years. While conventional wisdom suggests that central venous catheters increase infection risk, this comprehensive analysis reveals the mortality gap stems from broader vascular complications beyond just infections. Researchers tracked 146,967 dialysis patients across four years, finding that those using arteriovenous fistulas or grafts survived a median of 184 days longer initially, extending to 778 additional days when sustained over time. The study employed sophisticated statistical methods to account for the fact that sicker patients typically receive catheters, using inverse probability weighting to isolate the true impact of access choice. After adjusting for patient complexity, arteriovenous access reduced mortality risk by 25% initially and 62% when maintained long-term. This represents one of the largest real-world analyses of dialysis access outcomes, providing definitive evidence that vascular access choice directly influences survival rather than merely correlating with patient health status. The finding challenges the common practice of defaulting to temporary catheters, particularly given that infection-related deaths comprised only 8-10% of fatalities across all groups. For the 500,000 Americans requiring dialysis, this data suggests aggressive pursuit of permanent vascular access could meaningfully extend lifespan, making access creation a longevity intervention rather than simply a procedural preference.